
Please try another search
For the fiscal year ended 31 December 2021, Neuren Pharmaceuticals Ltd revenues decreased 72% to A$41K. Net loss decreased 15% to A$7.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects R&D Expense - Tax Credit increase from A$717K to A$3.2M (income), Foreign exchange loss decrease from A$631K (expense) to A$0K.
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 0.02 | 0.02 | 0.06 | 0.09 |
Gross Profit | ||||
Operating Income | -0.02 | -8.17 | -3.43 | -5.23 |
Net Income | 0.17 | -7.96 | -4.43 | -4.76 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 40.06 | 19 | 24.95 | 9.69 |
Total Liabilities | 0.8 | 2.35 | 0.75 | 0.6 |
Total Equity | 39.25 | 16.64 | 24.2 | 9.09 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | -9.97 | -6.14 | -8.08 | -5.15 |
Cash From Investing Activities | -0.01 | -0.01 | -0.01 | -0.01 |
Cash From Financing Activities | 22.18 | 0 | 19.14 | 0.14 |
Net Change in Cash | 12.6 | -5.97 | 10.34 | -4.67 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review